MDxHealth SA (MDXH)
| Market Cap | 24.48M -74.9% |
| Revenue (ttm) | 110.97M +17.4% |
| Net Income | -33.18M |
| EPS | -0.65 |
| Shares Out | 51.36M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 949,201 |
| Open | 0.5194 |
| Previous Close | 0.5070 |
| Day's Range | 0.4620 - 0.5400 |
| 52-Week Range | 0.4000 - 5.3300 |
| Beta | -506,809.90 |
| Analysts | Buy |
| Price Target | 2.90 (+508.6%) |
| Earnings Date | Aug 13, 2026 |
About MDXH
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. The company’s testing solutions include Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient’s previously biopsied negative tissue; ExoD, a non-invasive urine test to assess risk of having clinically prostate cancer; and Resolve mdx for urinary tract infection that identifies personalized effective antibiotic options a... [Read more]
Financial Performance
In 2025, MDxHealth's revenue was $107.88 million, an increase of 19.80% compared to the previous year's $90.05 million. Losses were -$33.52 million, -11.95% less than in 2024.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for MDXH stock is "Buy." The 12-month stock price target is $2.9, which is an increase of 508.60% from the latest price.
News
MDxHealth receives noncompliance letter from Nasdsaq
Mdxhealth (MDXH) announced that the company received a notification letter from Nasdaq, notifying the company that it is not in compliance with the minimum bid price requirement set forth in…
Mdxhealth Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
IRVINE, California – July 2, 2026 (GlobeNewswire) – Mdxhealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leader in urology-focused precision diagnostics, today announced that the Company rece...
Mdxhealth Announces Peer-Reviewed Publication of Oxford GPS-ProMPT Study in European Urology Oncology, Establishing Scientific Foundation for the Landmark GPS-ProtecT Randomized Controlled Trial
Mdxhealth Announces Peer-Reviewed Publication of Oxford GPS-ProMPT Study in European Urology Oncology, Establishing Scientific Foundation for the Landmark GPS-ProtecT Randomized Controlled Trial IRVIN...
MDxHealth Slides: Corporate presentation
MDxHealth has posted slides in relation to its latest quarterly earnings report, which was published on June 1, 2026.
MDxHealth price target lowered to $5 from $9 at Lake Street
Lake Street lowered the firm’s price target on MDxHealth (MDXH) to $5 from $9 and keeps a Buy rating on the shares. MDxHealth announced its Q1 results and the discontinuation…
MDxHealth price target lowered to $1.50 from $7 at TD Cowen
TD Cowen analyst Dan Brennan lowered the firm’s price target on MDxHealth (MDXH) to $1.50 from $7 and keeps a Buy rating on the shares. The firm said 1Q was…
MDxHealth downgraded to Market Perform from Outperform at William Blair
William Blair downgraded MDxHealth (MDXH) to Market Perform from Outperform without a price target The company’s Q1 revenue came in well below expectations and its full-year revenue guidance was cut…
MDxHealth price target lowered to $4 from $7 at BTIG
BTIG lowered the firm’s price target on MDxHealth (MDXH) to $4 from $7 and keeps a Buy rating on the shares after its Q1 miss and “material guidedown for 2026”.
MDxHealth to exit the Resolve mdx business
As part of its Q1 results announcement last night, the company stated: “On April 20, 2026, the Company received a Medicare contractor recoupment decision from Novitas Solutions totaling approximately ...
MDxHealth sees FY26 revenue $110M-$115M, consensus $118.6M
The company stated: “By streamlining our operations and removing the reimbursement volatility associated with Resolve, we are effectively resetting our growth trajectory for the remainder of the year....
MDxHealth Earnings Call Transcript: Q1 2026
Revenue for core prostate cancer diagnostics grew 11% year-over-year, with updated 2026 guidance of $110–$115 million (20–26% growth). The company exited the Resolve UTI business due to reimbursement uncertainty and is focusing on AI-driven innovation and operational efficiency.
MDxHealth Earnings release: Q1 2026
MDxHealth released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
MDxHealth reports Q1 EPS (17c) vs. (19c) last year
Reports Q1 revenue $27.39M, consensus $26.19M. Michael McGarrity, CEO of mdxhealth (MDXH), commented: “As we prioritized the integration of our recently acquired ExoDx business and to allow for renewe...
Mdxhealth Reports Q1-2026 Results
Mdxhealth Reports Q1-2026 Results Conference call with Q&A today at 4:30 PM ET / 22:30 CET IRVINE, California – May 13, 2026 (GlobeNewswire) – Mdxhealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"...
MDxHealth Slides: Corporate presentation
MDxHealth has posted slides in relation to its latest quarterly earnings report, which was published on May 4, 2026.
Mdxhealth to Release First Quarter 2026 Financial Results on May 13
Mdxhealth SA (NASDAQ: MDXH), a leading precision diagnostics company, today announced it will release its financial results for the first quarter ended Mar
MDxHealth management to meet virtually with Willlam Blair
Virtual Meeting to be held on March 19 hosted by William Blair.
Mdxhealth Highlights Data from Oxford's ProMPT Study Demonstrating the Genomic Prostate Score GPS Test Predicts Adverse Outcomes Across Multiple Treatment Settings at EAU 2026
Mdxhealth Highlights Data from Oxford's ProMPT Study Demonstrating the Genomic Prostate Score GPS Test Predicts Adverse Outcomes Across Multiple Treatment Settings at EAU 2026
MDxHealth Slides: Corporate presentation
MDxHealth has posted slides in relation to its latest quarterly earnings report, which was published on March 9, 2026.
MDxHealth Earnings Call Transcript: Q4 2025
Q4 and full-year 2025 saw strong revenue growth, driven by the ExoDx integration and balanced expansion across tissue and liquid biopsy segments. 2026 guidance targets 28% revenue growth and a 10% EBITDA margin, supported by disciplined capital allocation and operational efficiencies.
MDxHealth Annual report: Q4 2025
MDxHealth has published its Q4 2025 annual report on February 26, 2026.
MDxHealth Earnings release: Q4 2025
MDxHealth released its Q4 2025 earnings on February 26, 2026, summarizing the period's financial results.
MDxHealth reports Q4 EPS (17c) vs. (14c) last year
Reports Q4 revenue $29.55M, consensus $26.02M. Michael McGarrity, CEO of mdxhealth (MDXH), commented: “We are pleased to report another year of 20% revenue growth which reflects continued operating di...
Mdxhealth to Present Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on February 26
Mdxhealth to Present Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on February 26 Company to Host Conference Call with Live Q&A, February 26, 2026, at 4:30pm ET / 22:30 CET ...
MDxHealth Registration statement: Registration Filing
MDxHealth filed a registration statement on February 11, 2026, providing details about a securities offering with the SEC.